5875-25-2

Basic information

• Product Name: 2-BROMOPROPIONAMIDE
• Synonyms: 2-BROMOPROPIONAMIDE;2-BROMOPROPANAMIDE;2-bromo-propionamid;alpha-bromopropionamide
• CAS NO: 5875-25-2
• Molecular Formula: C₃H₆BrNO
• Molecular Weight: 151.99
• Product Categories: Amides;Carbonyl Compounds;Organic Building Blocks
• Mol File: 5875-25-2.mol
• Article Data: 5

Chemical Properties

• Melting Point: 123-125 °C(lit.)
• Boiling Point: 248.3 °C at 760 mmHg
• Flash Point: 104 °C
• Appearance: /
• Density: 1.644g/cm³
• Vapor Pressure: 0.0244mmHg at 25°C
• Refractive Index: 1.5
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: Benzene (Slightly), Chloroform (Slightly)
• PKA: 14.79±0.50(Predicted)
• CAS DataBase Reference: 2-BROMOPROPIONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOPROPIONAMIDE(5875-25-2)
• EPA Substance Registry System: 2-BROMOPROPIONAMIDE(5875-25-2)

Safety Data

• Hazard Codes: Xi
• WGK Germany: 3
• RTECS: UE3168680
• Hazardous Substances Data: 5875-25-2(Hazardous Substances Data)

Usage

Uses

2-Bromopropanamide is a reagent used in the preparation of arylamines via amination of phenols, synthesis of phenylurea derivatives as potent antitumor agents..

General Description

The hydrolytic dehalogenation of 2-bromopropionamide was catalyzed by dl-2-haloacid dehalogenase from Pseudomonas putida PP3 (dl-DEX 312).

InChI:InChI=1/C3H6BrNO/c1-2(4)3(5)6/h2H,1H3,(H2,5,6)

Upstream product

• 19481-82-4 2-bromopropionitrile 
• 32644-15-8 (S)-2-bromopropanoic acid 
• 7148-74-5 (S)-2-bromopropionyl chloride 
• 79-37-8 oxalyl dichloride 

Downstream Products

• 557-91-5 1,1-Dibromoethane 
• 19481-82-4 2-bromopropionitrile 
• 19481-82-4 (2S)-2-bromopropanenitrile 
• 14198-45-9 N-phenyl-2-(phenylamino)propanamide 
• 69506-15-6 2-(2,6-Diethyl-phenylamino)-propionamide 
• 69506-14-5 2-(2-Ethyl-6-methyl-phenylamino)-propionamide 
• 24956-48-7 2-methyl-3-oxo-3-phenyl-propionic acid amide 
• 69506-16-7 2-(2,6-Dimethyl-phenylamino)-propionamide 
• 99855-83-1 (1-carbamoyl-ethylsulfanyl)-phenyl-acetic acid 
• 53296-04-1 (1-carbamoyl-ethyl)-dimethyl-phenyl-phosphonium; bromide 
• 74537-45-4 2-(5-chloro-benzothiazol-2-ylsulfanyl)-propionamide 
• 132033-10-4 2-(4-Butylsulfanyl-6-phenylamino-pyrimidin-2-ylsulfanyl)-propionamide 
• 76809-54-6 N-benzylidene-(1-carbamoyl)-ethylamine N-oxide 
• 849585-22-4 LACTIC ACID 

Relevant articles and documents

Method for manufacturing isavuconazole or ravuconazole

The invention provides a method for manufacturing a triazole compound isavuconazole or ravuconazole which is enriched by a diastereoisomer and enantiomer. The method comprises the following steps: a Reformatsky reaction is carried out between ketone and dihalogeno metal propionitrile; an enantiomer mixture is generated, and separation is carried out. The method can obviously reduce steps for synthesis of isavuconazole or ravuconazole, yield of products is improved, and production cost is reduced.

Synthesis of enantiomerically enriched-bromonitriles from amino acids

Two methods were investigated for the preparation of six chiral-bromonitriles with different optic purities. The nitrous deamination of amino acids gives-bromoacids, which react with chlorosulfonyl isocyanate followed by triethylamine to afford-bromonitriles with moderate enantiomeric excess. However, the dehydration of corresponding-bromoamids using thionyl chloride gives-bromonitriles with good enantiomeric excess up to 94%. The use of phosphoryl chloride instead of thionyl chloride results in more than 30% racemization as determined by high-performance liquid chromatograpic analysis.

Multibinding inhibitors of microsomal triglyceride transferase protein

Disclosed are multibinding compounds which inhibit microsomal triglyceride transferase protein (MTP), a protein which mediates the transfer of lipids during the assembly of lipoproteins and related biomolecules. The multibinding compounds contain from 2 to 10 ligands covalently attached to one or more linkers. The multibinding compounds of this invention are useful for lowering serum lipid, cholesterol and/or triglyceride levels, and for preventing and treating disorders associated with hyperlipemia, hyperlipidemia, hyperlipoproteinemia, hypercholestrolemia, hypertriglyceridemia and the like, such atherosclerosis.